Patients aged above 18 years with de novo AML or secondary. Patients aged above 18 years with de novo AML or secondary. and AML molecular mutation profile by next-generation sequencing.
Conditions
Interventions
(1) Patients aged above 18 years
(2) Patients with de novo AML or secondary AML
(3) Patients with molecular mutation profile by next-generation sequencing
(4) Patients who signed informed consent of
Other
Patients aged above 18 years with de novo AML or secondary. and AML molecular mutation profile by next-generation sequencing.
Sponsors
Siriraj Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to 18 Years
Inclusion criteria
Inclusion criteria: (1) Patients aged above 18 years (2) Patients with de novo AML or secondary AML (3) Patients with molecular mutation profile by next-generation sequencing (4) Patients who signed informed consent of AML registry study (793/2560 (EC2)
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed acute promyelocytic leukemia (APL)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing 1-year OS rate between RUNX1 mutation and RUNX1 wild-type groups 1 year The duration between diagnosis and either death or last follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparing CR rates between RUNX1 mutation and RUNX1 wild-type groups 2 months The percentage of patients who have BM blasts below 5%, the absence of extramedullary blasts, with an ANC more than 1000/mcL, and a plt more than 100000/mcL after induction treatment, Comparing 1-year RFS rate between RUNX1 mutation and RUNX1 wild-type groups 1 year The duration from the CR date to relapse or death from any cause,Studying significant factors associated with OS and RFS 1 year Comparing factors associated with survival outcomes between RUNX1 mutation and RUNX1 wild-type groups | — |
Countries
Thailand
Contacts
Public ContactWeerapat Owattanapanich
Division of Hematology ,Faculty of Medicine Siriraj Hospital, Mahidol University .
Outcome results
None listed